Directorate Change
01/07/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240701:nRSA4626Ua&default-theme=true
RNS Number : 4626U Niox Group PLC 01 July 2024
NIOX GROUP PLC
("NIOX" or the "Company" and, together with its subsidiaries, the "Group")
Directorate Change
Oxford, UK - 1 July 2024: NIOX Group plc (AIM: NIOX), a medical device company
focused on point of care asthma diagnosis and management, is pleased to
announce the appointment of Robert Naylor as Non-Executive Director and Chair
of the Audit and Risk Committee, with immediate effect.
Robert has over 25 years' experience in capital markets specialising in
healthcare and investment companies and is currently Chief Executive Officer
of Intuitive Investments Group plc, an investment company which is quoted on
the Specialist Fund Segment of the London Stock Exchange's Main Market,
providing investors with exposure to a portfolio of fast-growing technology
and life sciences businesses. Additionally, Robert is Non-Executive Chairman
of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently
subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed
company indirectly wholly-owned by investment funds advised by affiliates of
Blackstone Inc.
Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund
Limited and oversaw its sale to a company directly owned by Alchemy
Copyrights, LLC, trading as Concord. He has also served as a Non-Executive
Director of Light Science Technologies Holdings plc, an AIM-quoted controlled
environment agriculture company. Earlier in his career Robert held various
positions within JP Morgan Asset Management Limited, Panmure Gordon (UK)
Limited and Cenkos Securities plc. Robert is a qualified chartered accountant,
having started his career with Ernst & Young in 1996.
Ian Johnson, NIOX's Executive Chairman, said: "I am delighted to welcome
Robert to the NIOX Board and look forward to working with him as we continue
to build on our global leadership. Robert brings extensive business and
corporate development experience to assist the executive team in implementing
its growth strategy."
Additional information in respect of the AIM Rules
The following information regarding the appointment of Robert Graham Naylor
(aged 49) is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules
for Companies ("AIM Rules"):
Current directorships/partnerships Past directorships/partnerships
· Intuitive Investments Group Plc · Round Hill Music Royalty Fund Limited
· IIG Assets Ltd · RHMRF2 Limited
· Hipgnosis SFH XX Limited · RHMRF3 Limited
· Hipgnosis SFH XIII Limited · Light Science Technologies Holdings plc
· Hipgnosis SFH XIX Limited · Concord Copyrights No.1 Limited (formerly RHMRF1 Limited)
· Hipgnosis SFH I Limited
· Hipgnosis Holdings UK Limited
· Rubyruby (London) Limited
· Pb Songs Ltd
· Kennedy Publishing & Productions Limited
· Deamon Limited
As at the date of this announcement, Robert Naylor holds no interest in the
Company.
Save as set out above, there is no further information to be disclosed in
respect of Robert Naylor under Schedule 2(g) of the AIM Rules for Companies.
Contacts:
NIOX Group plc +44 (0) 3303 309 356
Ian Johnson, Executive Chairman
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Joint Broker) +44 (0) 20 7496 3000
Aubrey Powell / Jen Boorer / James Todd
Investec Bank plc (Financial Adviser and Joint Broker) +44 (0) 20 7597 4000
Edward Knight / Bruce Garrow / Lydia Zychowska
About NIOX
Our mission is to improve asthma diagnosis and management by greater patient
access to FeNO testing. Asthma is one of the biggest healthcare issues
globally with 340 million sufferers, many of whom are undiagnosed or are
misdiagnosed. The Group is engaged in the design, development, and
commercialisation of medical devices for the measurement of FeNO, a precise
biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly
recognised by healthcare professionals as an important tool to improve the
diagnosis and management of asthma. NIOX VERO® is also the device of choice
by leading clinical research organisations for respiratory studies.
NIOX provides products and services via its direct sales organisation and
extensive distributor network in 50 countries. For more information, please
visit www.niox.com (http://www.niox.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAQKFBBOBKDQAB